UnitedHealth Group (UNH) has attracted fresh attention after raising its full-year adjusted EPS guidance and lifting its quarterly dividend to US$2.32 per share, reinforcing management’s focus on margin recovery and cash flow resilience.

UnitedHealth Group’s share price has climbed recently, with a 30-day share price return of 3.5% and a 90-day share price return of 43.37%. The 1-year total shareholder return of 35.52% contrasts with a weaker 3-year total shareholder return, which suggests momentum has picked up after a tougher period.

If you are weighing UnitedHealth Group’s latest guidance against broader health-related themes, it can be helpful to see what else is moving in healthcare-focused technology, including 40 healthcare AI stocks.

With UnitedHealth Group trading near recent highs after strong EPS guidance and a higher dividend, plus an indicated intrinsic discount of about 55%, investors now face a key question: is the stock still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 3.2% Overvalued

Compared with UnitedHealth Group’s last close at $407.65, the most followed narrative fair value of $395.00 points to a small valuation gap that hinges on how investors view the Optum franchises versus the core insurance business.

Our thesis centers on the fact that the market is discounting the massive value of Optum (Insight, Health, and Rx). While the insurance arm (UnitedHealthcare) is undergoing a painful but necessary "right-sizing", shedding ~1.4M members to prioritize margins, Optum continues to scale. By buying UNH at a 13x-15x Forward P/E, investors are essentially acquiring the world’s most powerful healthcare data ecosystem at a "legacy utility" multiple.

The heart of this narrative is simple. Optum’s data and services, margin repair in UnitedHealthcare, and capital deployment assumptions all feed into that $395.00 fair value. Curious which earnings, cash flow and valuation levers matter most here.

Result: Fair Value of $395.00 (OVERVALUED)

However, investors still need to watch for tighter Medicare or broader regulatory changes, along with any setback in Optum’s execution that could challenge this UnitedHealth Group narrative.

Another View on UnitedHealth Group’s Value

The narrative fair value pegs UnitedHealth Group at $395.00 and labels the stock as slightly overvalued, but our DCF model points in a very different direction, with a fair value estimate of about $905.35. This suggests a wide implied undervaluation that investors need to think carefully about.

If you want to see how this SWS DCF model arrives at its number and what assumptions sit behind it, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UnitedHealth Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment around UnitedHealth Group, now is a good time to look at the numbers yourself, compare both sides, and decide where you stand, starting with 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond UnitedHealth Group?

If you only focus on UnitedHealth Group, you could miss other setups that fit your goals, so broaden your watchlist with a few targeted stock ideas.

• Target resilient income by reviewing 9 dividend fortresses that aim to combine higher yields with balance sheet strength.
• Hunt for potential mispricings by scanning 44 high quality undervalued stocks built around quality metrics and valuation signals.
• Prioritize capital preservation first and growth second by focusing on 67 resilient stocks with low risk scores tailored for steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.